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ABSTRACT
The tumor suppressor BRCA2 is essential for homol-
ogous recombination (HR), replication fork stability
and DNA interstrand crosslink (ICL) repair in verte-
brates. We show that ectopic production of HSF2BP,
a BRCA2-interacting protein required for meiotic HR
during mouse spermatogenesis, in non-germline hu-
man cells acutely sensitize them to ICL-inducing
agents (mitomycin C and cisplatin) and PARP in-
hibitors, resulting in a phenotype characteristic of
cells from Fanconi anemia (FA) patients. We bio-
chemically recapitulate the suppression of ICL re-
pair and establish that excess HSF2BP compromises
HR by triggering the removal of BRCA2 from the ICL
site and thereby preventing the loading of RAD51.
This establishes ectopic expression of a wild-type
meiotic protein in the absence of any other protein-
coding mutations as a new mechanism that can lead
to an FA-like cellular phenotype. Naturally occurring
elevated production of HSF2BP in tumors may be a
source of cancer-promoting genomic instability and
also a targetable vulnerability.
INTRODUCTION
BRCA2 is a large nuclear protein,mutations affecting it pre-
dispose to breast, ovarian and other forms of cancer (1).
The tumor suppressor activity of BRCA2 is attributed to its
functions in genome maintenance: error-free DNA double
strand break (DSB) repair by homologous recombination
(HR) and replication fork stabilization. These functions of
BRCA2 depend on its association with other HR proteins:
RAD51, PALB2 and BRCA1 (2), which also act as tumor
suppressors. We recently characterized a novel direct inter-
action of BRCA2 with the protein HSF2BP (3), which is
required for HR during meiosis (3,4). Physiological expres-
sion ofHSF2BP is restricted to germline and ES cells (3–5),
but we found that in some human tumors it is transcribed at
high levels. This raises the question whether ectopic produc-
tion of HSF2BP has a pathological effect on the function of
BRCA2 in somatic cancer-derived cells.
The role of BRCA2 in HR is believed to be in deliv-
ering RAD51 to the sites of damage, and in perform-
ing the ‘HR mediator’ function: replacing the single-
stranded DNA binding protein RPA with RAD51 (6).
BRCA2 further stabilizes the resulting RAD51 nucleopro-
tein filament that then executes homology recognition and
strand exchange reactions underlying most forms of HR.
Therefore, BRCA2-deficient cells cannot faithfully repair
DNA lesions that require HR. One example of such le-
sions are replication-associated DSBs that form when cells
are treated with poly (ADP-ribose) polymerase inhibitors
(PARPi), a new class of anticancer drugs (7). BRCA2 de-
ficiency is synthetically lethal with PARPi, which makes
these inhibitors promising chemotherapeutic agents for
HR-deficient tumors.
Another type of DNA damage that stalls replication and
results in replication-associated DSBs, which require HR
for repair, are DNA interstrand crosslinks (ICLs) (8). These
complex lesions arise from endogenous sources and are in-
duced by clinically important chemotherapeutic drugs such
as cisplatin and mitomycin C (MMC). ICL repair involves
a large group of proteins, named FANCA to FANCW in-
cluding BRCA2 (FANCD1), RAD51 (FANCR), PALB2
(FANCN) and BRCA1 (FANCS), known as the Fanconi
anemia (FA) pathway. Defects in this pathway cause the hu-
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man genetic cancer-predisposition syndrome FA (9). Cells
from FA patients are acutely sensitive to ICL-inducing
agents. Upon stalling of the replication machinery at the
ICL, the FA pathway is activated via ubiquitination of the
FANCD2-FANCI dimer by the FA core E3 ligase complex.
Ubiquitinated FANCI-FANCD2 promotes nucleolytic dis-
engagement of the crosslinked strands (‘lesion unhooking’)
by the XPF-ERCC1 nuclease (10) resulting in the genera-
tion of a DSB, which can be repaired by HR (11). The repli-
cation fork protection function of BRCA2, associated with
its C-terminal domain, likely also contributes to ICL repair,
because deletion of this domain sensitizes mouse cells to
ICL-inducing agents (12), and because in biochemical as-
says HR protein accumulation at the site of ICL precedes
DSB formation (11).
Although germline mutations in BRCA2 are responsible
for only a small fraction of total breast cancer cases (<5%),
many more tumors are functionally HR-deficient (e.g. ref.
13). This phenotypic resemblance (‘BRCAness’ (14)) is of
high clinical significance, as it can guide the selection of
treatment, in particular the use of PARPi and ICL-inducing
compounds. Genetic analysis of HR-deficient cancers is fo-
cused on identifying mutations that affect protein-coding
sequence (13). Similarly, known FA-causing mutations re-
sult in alteration of the protein coding sequence either di-
rectly or via splicing. Aberrant expression of a wild-type
gene, such as what we reported for the meiotic HR gene
HSF2BP, is generally not considered as a possible reason
for HR disfunction in tumors or as an underlying cause
of the FA. Since in most cases of tumors showing the BR-
CAness phenotype, as well as some cases of FA, the driver
factors have not been identified, exploring such additional
mechanisms can be clinically highly relevant.
Ectopic activation of the germline genes in cancer is
ubiquitous and may be one of its hallmarks (15–18). Hun-
dreds such genes have been identified, primarily as poten-
tial targets for anti-tumor immune therapy (‘cancer/testis
antigens’ (CTA)) (15,19–20). For nearly all of them, the
physiological function in the germline and the pathological
role in cancer are unknown. The idea that ectopic expres-
sion is not epiphenomenal but contributes to cancer evolu-
tion and possibly even emergence is conceptually appeal-
ing (21,22), but remains largely untested. Given the cen-
tral role genomic instability plays in tumorigenesis, many
properties of meiotic DNA metabolism may be particu-
larly relevant. However, only few out of hundreds of ectopi-
cally expressed germline-specific proteins have been shown
to affect genome stability (21,23–30). Notably, two synap-
tonemal complex proteins were reported to affect mitotic
HR, by either promoting (HORMAD1 (28,29)) or inhibit-
ing it (SYCP3 (24) and also HORMAD1 (30)), although
the mechanisms or relation to meiosis are not clear. Pro-
viding more detailed mechanistic understanding of such ef-
fects and connecting them to physiological roles would be
extremely informative for both molecular oncology and re-
productive biology fields.
In this report, we show that elevated ectopic production
of HSF2BP in human cancer cells, through its interaction
with BRCA2, disrupts HR in the context of ICL repair,
phenocopying FA patient cells, and sensitizes cells to ICL-
inducing agents and PARPi. The mechanism of ICL repair
disruption by HSF2BP involves removal of BRCA2 from
the ICL followed by proteasomal degradation. This reduces
RAD51 accumulation at ICL damage site, thus inhibiting
the HR step of the FA pathway of ICL repair. We demon-
strate that the HSF2BP meiotic protein is a novel negative
regulator of BRCA2 in somatic cells and propose that it
could be exploited in cancer therapy.
MATERIALS AND METHODS
Cell culture
HeLa, U2OS, MDA-MB-157, HEK293T and RT-112 cells
were cultured in DMEM, supplemented with 10% (v/v) fe-
tal calf serum (FCS), 200 U/ml penicillin, 200 g/ml strep-
tomycin. HCC1187 were cultured in RPMI-1640 supple-
mented with 10% FCS, 200 U/ml penicillin, 200 g/ml
streptomycin and 0.25 g/ml gentamycin.
Generation of genetically modified cell lines
With the exception of U2OS GFP-HSF2BP clone #5, all
stable cell lines were constructed using PiggyBac vectors by
co-transfecting them with the transposase expression con-
struct (mPB (31) or hyPBase (32)), followed by selection
with either 1.5 g/ml puromycin or 800 g/ml G418, de-
pending on the construct, maintained for 6–10 days. Stable
transformation was highly efficient (>95% GPF-positive
cells when GFP-tagged constructs were used) and there-
fore clonal isolation was not performed. Stable line U2OS
GFP-HSF2BP clone #5 used in the initial experiments
(Figure 1A–C) was constructed by random integration of
pEGPFN1-HSF2BP construct with 800 g/ml G418 selec-
tion. Several GFP-positive individual clones were isolated,
expanded and checked for uniform expression of single ma-
jor GFP-fused protein by FACS and immunoblotting.
BRCA2Δ12/Δ12 cell lines were produced by transfect-
ing HeLa cells with sgRNA cloned into pX459 Cas9 ex-
pression vector (33). Target sequences for sgRNAs in in-
trons 11 and 12 were CTATTTAACAGGGTCTAAAC and
AGTGACAATACTTATTGCCG, respectively. Cells were
cloned by limiting dilution and screened by PCR for the loss
or inversion of the targeted region (primers F1: TTGTTA
GGCCTTATTGCCAGT, R: AGCTAATTTTACCATC
TGGAGTGC and R3: CCTTTTACTTGAAAGAATAA
CCAAC). Positive clones were expanded, and loss of wild-
type transcript was verified byRT-PCRwith primers A: CA
CCTACGTCTAGACAAAATGTATC, B: GTGCCATC
TGGAGTGCTTTT, C: GCCTGGCTGTGGAAAGAC
GCGTTGCCTTTG and D: GGCATCTATTAGCAAA
TTCCTTAGGAAAGGCACATTCCAT.
Expression constructs
Cloning of human and mouse HSF2BP from U2OS and
mES IB10 cells and engineering of GFP-HSF2BP expres-
sion constructs was described previously (3). Untagged
HSF2BP expression constructs were produced similarly, in
the same PiggyBac vectors (34) using PCR amplification
and Gibson assembly (35). Details of the PCR primers and
cloning strategies are available upon request.
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Lentiviral shRNA transduction
shRNA expression constructs were obtained from the
Sigma mission library (TRC 1.5). Lentiviral packaging
plasmids (pMDLg/pRRE, pRSV-REV and pMD2.G)
and shRNA expression constructs were transfected into
HEK293T cells using calcium phosphate precipitation:
HEK293T cells were seeded at a density of 12–20 × 106
per 10-cm culture dish in 17 ml media; transfection was
performed within 1–6 h after seeding: 30 g DNA (12
g lentiviral genome and 6 g of each of the packag-
ing plasmid) was dissolved in 900 l deionized water and
mixed with 100 l 2.5 M CaCl2, 1 ml of 2 × HBS buffer
(50 mM HEPES, 280 mM NaCl, 1.5 mM Na2HPO4,
pH 7.1 with NaOH, filter-sterilized) was added dropwise,
while air bubbles were passed through the DNA solu-
tion to ensure mixing. Transfection mix was added to the
plates containing HEK293T cells dropwise within 5–10
min after mixing; 24 h after transfection the medium was
changed and 48 h after transfection the supernatant of
the HEK293T cells was added to U2OS cells. This pro-
cess was repeated the next day. Forty-eight hours after the
second transduction, selection with 1.5 g/ml puromycin
was started. Two of the five tested shRNAs efficiently re-
duced the concentration of overproduced GFP-HSF2BP:
#2 (clone TRCN0000017473, target sequence GCTGGA
ATTGTCACGAATGTT) and #3 (clone TRCN00000174
76, target sequence GCTAATGCTGATGTCCCTATA);
constructs SHC001 (empty vector) and SHC003 (non-
targeting shRNA) from the same library were used as neg-
ative controls.
Clonogenic survivals
Clonogenic survivals were performed in 6-well plates with
technical duplicates or triplicates and done at least twice.
Cells maintained in 6-well plates before the start of exper-
iment were trypsinized and counted either manually, us-
ing Z2 counter (Beckman Coulter) or using Countess II
counter (Thermo). The basal seeding density of 100 cells
per untreated well was adjusted in dose-dependent man-
ner to account for plating efficiency reduction due to treat-
ment. Olaparib (AstraZeneca, AZD2281) and talazoparib
(BMN 674, Axon Medchem) were added to the media on
the day of seeding after cells became attached. Media was
replaced 4 days after olaparib addition. MMC treatment
was performed one day after seeding; after 2 h incubation
withMMC,mediawere removed, cells were rinsedwith PBS
and 2 ml fresh media were added. After 6–8 days plates
were rinsed with PBS, stained with Coomassie brilliant blue
R (0.025% in 40% methanol, 10% acetic acid), and macro-
scopically visible colonies were counted manually or using
the OpenCFU software (36). In the figure legends, n indi-
cates the number of biological replicates, error bars indicate
s.e.m. between means of technical replicates in each experi-
ment where n ≥ 3, or between all individual technical repli-
cates in experiments with n = 2. For genetically engineered
BRCA2 12 cells, three independent clones were used per
genotype and considered as biological replicates when cal-
culating the mean.
DR-GFP assay
U2OS cells carrying the reporter (clone U2OS-18 (37))
were transfected with the PiggyBac expression construct
for HSF2BP or empty vector, and the construct encoding
transposase, stable integrants were selected with 800 g/ml
G418. The stably transformed U2OS-18 derivatives were
seeded into 6-well plates at 2 × 105 cells per well and trans-
fected next day using XtremeGene reagent with 2 g of
either I-SceI expression plasmid (pCBASceI), empty vec-
tor or pEGFP-N1 as transfection control efficiency control.
FACS analysis was performed 2 days after transfection as
previously described (38) but a BD LSRFortessa cell ana-
lyzer was used.
Antibodies
Antibodies used in this study were against RAD51 (rab-
bit 2307 (39)), FANCD2 (NB 100-316, Novus Biologicals),
H2B (07-371, Millipore), MSH2 (Ab-2, Oncogene), HSP90
(ab13492, Abcam), BRCA2 (Ab-1, OP95, Calbiochem),
GFP (clones 7.1 and 13.1, Roche), PARP-1 (C2-10, Enzo),
6xHis tag (ab18184, Abcam), Actin (clone C4, MAB1501,
Millipore) and ubiquitin (sc-8017, Santa Cruz Biotechnol-
ogy). Anti-HSF2BP rabbit polyclonal antibodies SY8126
and SY8127 were raised against purified recombinant un-
tagged human HSF2BP (Kaneka Eurogentec, Belgium)
and used either as crude serum or after affinity purifi-
cation against GST-HSF2BP immobilized on glutathione
sepharose as described (40). Antibodies against Xenopus
laevis (xl) REV1, xlXPF,xlERCC1, xlBRCA2, xlPCNA and
xlFANCD2 were previously described (3,10,41–44).
Immunoblotting and cell fractionation
To prepare total protein lysates, cells were scraped in PBS
or collected by trypsinization and lysed in 2×Laemmli SDS
loading buffer (120 mM Tris pH 6.8, 4% SDS, 10% glyc-
erol), after determining the protein concentration in the
lysate by Lowry method, the lysate was complemented with
10× reducing additive (0.1% bromophenol blue, 0.5% -
mercaptoethanol). For fractionation (45), 1 million cells
were collected by trypsinization, washed with ice-cold PBS,
re-suspended in Schaffner’s lysis buffer (10 mM HEPES-
NaOH pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA, 1 mM dithiothreitol (DTT), protease inhibitor
cocktail); after 15-min incubation on ice NP-40 was added
to the final concentration 0.1% and solution was vortexed.
Nuclei were pelleted by 30 s centrifugation at 18 000 rcf,
re-suspended by shaking for 15 min at 4◦C in nuclear ex-
traction buffer (20 mM HEPES-NaOH pH 7.9, 400 mM
KCl, 1 mM EDTA, 1 mM EGTA, 1 mMDTT, protease in-
hibitor cocktail) and centrifuged for 5 min at 18 000 rcf to
separate chromatin pellet from soluble nucleoplasmic frac-
tion; the pellet was re-suspended in Laemmli SDS loading
buffer. Proteins were separated on polyacrylamide hand-
cast tris-glycine or bis-tris, or precast bis-tris or tris-acetate
gels (Novex) and blotted on nitrocellulose or PVDF mem-
branes. For hHSF2BP immunodetection with SY8126 an-
tibody in whole cell extracts, hand-cast bis-tris gels were
used (14% acrylamide/bis 37.5; 3.5× Bis-Tris gel buffer
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(1.25 M Bis-Tris HCl, pH 6.6) diluted to 1× with water)
and run with theMES-SDS running buffer (ThermoFisher,
NP0002) at 100 V for 5 h. For BRCA2 detection 4–8% pre-
cast tris-acetate gels were used, and transfer was performed
in 2× Towbin transfer buffer (50 mMTris, 384 mM glycine,
20% methanol) at 300 mA constant current for 2 h at 4◦C
to PVDF membrane. Membranes were blocked in 5% milk
in PBS supplemented with 0.05% Tween. After overnight
incubation with the primary antibody, membranes were
washed in PBS supplemented with 0.05% Tween and in-
cubated with horseradish peroxidase-conjugated secondary
antibodies (Jackson Immunoreserach). Blots were devel-
oped using homemade ECL reagents and detected with
the Alliance 4.7 (UVItec) or Amersham Imager 600 (GE
Healthcare).
Protein purification
Human HSF2BP, human HSF2BP variant R200T and
Xenopus laevis HSF2BP were purified as previously de-
scribed (3). For the purification of FLAG-His tagged ubiq-
uitin, the cDNA encoding Xenopus laevis ubiquitin was
ligated into pETDuet-1 vector. The ubiquitin protein was
overexpressed with a N-terminal FLAG-His tag in E. coli
BL21(DE3) cells at 30◦C and purified withNi-NTA agarose
resin by the samemethod asXenopus laevisHSF2BP. Eluted
protein was dialyzed against 2 mM -mercaptoethanol (4
l) overnight and then applied to 30 kDa MWCO Amicon
Ultra-15 centrifugal filter unit (Millipore). After centrifu-
gation, flow-through was collected, concentrated using 3
kDa MWCO Amicon Ultra-15 centrifugal filter unit (Mil-
lipore) and flash frozen with liquid nitrogen. The concen-
tration of the proteins was determined by SDS-PAGE with
Coomassie Brilliant Blue staining, using BSA as the stan-
dard protein.
Xenopus egg extracts, immunodepletion, DNA replication,
repair assay and lesion bypass assay
DNA replication and preparation of Xenopus egg extracts
(HSS and NPE) were performed as described previously
(46,47). Preparation of plasmid with a site-specific cisplatin
ICL (pICL) and ICL repair assays was performed as de-
scribed (43,48). Briefly, pICL (9 ng/l) and pQuant (0.45
ng/l) were first incubated in a high-speed supernatant
(HSS) of egg cytoplasm for 20 min at ∼20◦C, which pro-
motes the assembly of prereplication complexes on the
DNA. Addition of two volumes nucleoplasmic egg extract
(NPE), which also contained 32P--dCTP, triggers a sin-
gle round of DNA replication.Where indicated, His-tagged
human HSF2BP (0.45 M) or His-tagged Xenopus lae-
vis HSF2BP (0.45 M), FLAG-His tagged ubiquitin (0.11
g/l), MG-132 (0.38 mM) or NMS-873 (0.2 mM) was
added to NPE prior to mixing with HSS. Aliquots of repli-
cation reaction (3.8 l) were stopped at various times with
45 l Stop solution II (50 mM Tris pH 7.5, 0.5% SDS and
10 mMEDTA,). Samples were incubated with RNase (0.13
g/l) for 30 min at 37◦C followed by proteinase K (0.5
g/l) overnight at room temperature. DNAwas extracted
using phenol/chloroform, ethanol-precipitated in the pres-
ence of glycogen (30 mg/ml) and resuspended in 3.8 l TE
(10 mM Tris pH 7.5 and 1 mM EDTA). ICL repair was
analyzed by digesting 1 l extracted DNA with HincII, or
HincII and SapI, separation on a 0.8% agarose gel in 1×
TBE buffer, and quantification using Typhoon TRIO+ (GE
Healthcare) and ImageQuant TL software (GE Health-
care). Repair efficiency was calculated as described (49).
For lesion bypass assay, the digested DNA was ethanol-
precipitated, and resuspended in 12 l alkaline loading
buffer (50 mMNaOH, 1 mM EDTA and 2.5% Ficoll-400).
Fragments were then separated on a 0.8% agarose gel in
alkaline buffer (50 mM NaOH and 1 mM EDTA), after
which the gel was dried on Amersham Hybond-XL mem-
brane (GE Healthcare) and exposed to a phosphor screen.
The band intensity of the bypassed product was quanti-
fied with Typhoon TRIO+ using ImageQuant TL software
(GE Healthcare). The highest value was set at 100% for the
bypassed product. Immunodepletion of the XPF-ERCC1
complex was performed using Protein A Sepharose Fast
Flow (PAS) beads (GE Healthcare) as previously described
(10).
Immunofluorescence and microscopy
HeLa cells were treated overnight with 100 nM or for 2–
4 h with 1.2 M MMC, washed with PBS, pre-extracted
before fixation for 1 min in Triton X-100 buffer (0.5% Tri-
ton X-100, 20 mM HEPES-KOH pH 7.9, 50 mM NaCl, 3
mM MgCl2, 300 mM sucrose), fixed in 2% paraformalde-
hyde in PBS and stained as described (50). In short-term
treatment experiments, EdU was added to final concentra-
tion 10 M30 min before pre-extraction and fixation. Cells
were then permeabilized with 0.5% Triton in PBS, washed
with 3% BSA in PBS; Atto-594 azide (Atto Tec, #594–105,
final concentration 60 M) conjugation reaction was per-
formed in 50 mMTris pH 7.5, 4 mMCuSO4, 10 mM ascor-
bic acid, followed by RAD51 immunofluorescence staining.
Pictures were taken using a Leica SP5 confocal microscope
using a 63× objective and 405, 488 and 594 nm lasers. Sta-
tistical analysis was performed in Graphpad Prism using a
Kruskal–Wallis test with Dunn’s post-test.
Incision assay
Incision assay was performed as described previously
(10,51). Briefly, pICL (225 ng) and pQuant (11.3 ng) were
incubated with 1.5 units NB-BSR DI enzyme (NEB) in
1× NEBuffer 2.1 for 30 min at room temperature. Sub-
sequently, the nick translation reaction was initiated by
adding 11 l DNA Polymerase I mix (5 units DNA poly-
merase I (NEB), dATP, dGTP, dTTP (0.5 mM each), dCTP
(0.4 M) and 32P--dCTP (3.3 M) in 1 × NEBuffer 2.1)
and incubation for 3 min at 16◦C. The reaction was stopped
with 180l Stop Solution II, treatedwith proteinaseK (0.24
mg/ml) and phenol/chloroform-extracted. After excess la-
bel was removed using a Micro Bio-Spin 6 Column (Bio-
Rad), plasmids were ethanol-precipitated, and resuspended
in 5 l ELB (10 mM HEPES-NaOH pH 7.7, 50 mM KCl,
2.5 mMMgCl2 and 250 mM Sucrose). The labeled plasmid
was used in a replication reaction and samples at various
times were extracted and digested with HincII. Fragments
were separated on a 0.8% denaturing agarose gel in alkaline
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/48/5/2442/5710778 by guest on 17 M
arch 2020
2446 Nucleic Acids Research, 2020, Vol. 48, No. 5
buffer, after which the gel was dried onAmershamHybond-
XLmembrane and exposed to a phosphor screen. The band
intensity of the X-shape structure was measured with Ty-
phoon TRIO+ and quantified using ImageQuant TL soft-
ware. The highest value was set at 100% for the X-shape
structure.
Two-dimensional gel electrophoresis (2DGE)
2DGE was performed as described previously (11). Repli-
cation samples of pICL at various times were extracted
and digested with HincII. Fragments were then analyzed by
2DGE. The first dimension gel consisted of 0.4% agarose
run in 0.5× TBE buffer at 0.86 V/cm for 24 h at room tem-
perature. The lanes of interest were cut out, casted across the
top of the second-dimension gel consisting of 1% agarose
with 0.3 g/ml ethidium bromide, and run in 0.5× TBE
containing 0.3 g/ml ethidium bromide with buffer circu-
lation at 3.5 V/cm for 14.5 h at room temperature. The gel
was dried on Amersham Hybond-XL membrane and ex-
posed to a phosphor screen. DNA was visualized using a
Typhoon TRIO+.
Plasmid pull-down assay
Plasmid pull-down assay was performed as described previ-
ously withmodifications (41). At the indicated times, 5l of
the pICL replication samples were mixed with 3.75 l LacI-
coupledmagnetic beads (DynabeadsM-280; Life Technolo-
gies) suspended in 25 l ELB containing 0.25 mg/ml BSA,
2.5 mM CaCl2 and 0.03% Tween 20, and incubated for 30
min on ice. The beads were washed three times with 37.5
l ELB containing 0.25 mg/ml BSA, 2.5 mM CaCl2 and
0.02% Tween 20, dried, and suspended in 20 l 1× SDS
sample buffer. Plasmid-bound proteins were then separated
by SDS-PAGE and visualized by western blotting using the
indicated antibodies.
Chromatin immunoprecipitation (ChIP)
ChIP was performed as described previously (52). At the
indicated times, pICL replication samples were crosslinked
with ELB containing 1% formaldehyde for 10 min at room
temperature. A non-related undamaged control plasmid
(pQuant) was added to the replication reactions to assess
background binding of the proteins. After quenching the
formaldehyde by addition of glycine (125 mM final con-
centration), the samples were passed through a Micro Bio-
Spin 6 Chromatography column (Bio-Rad), sonicated and
immunoprecipitated with 5 g of the indicated antibodies
bound to PAS beads. The protein-bound DNA fragments
were elutedwithChIP elution buffer (50mMTris pH 7.5, 10
mM EDTA and 1% SDS) and the crosslinks were reversed
by incubation at 42◦C for 6 h and subsequently at 70◦C for
9 h. DNA was then phenol/chloroform-extracted, followed
by quantitative real-time PCR in 10 l reaction buffer (6
mMTris pH 8.3, 25 mMKCl, 2.5 mMMgCl2, 0.1% Tween-
20, 0.1 mg/ml BSA, 0.3 mM dNTPs, 1:66,500 SYBRGreen
I (Sigma-Aldrich), and Hot Start Taq DNA polymerase),
using 0.25 M of following primers: pICL (5′-AGCCAG
ATTTTTCCTCCTCTC-3′ and 5′-CATGCATTGGTTCT
GCACTT-3′) and pQuant (5′-TACAAATGTACGGCCA
GCAA-3′ and 5′-GAGTATGAGGGAAGCGGTGA-3′).
The values from pQuant primers were subtracted from the
values for pICL primers. Antibodies used for ChIPwere pu-
rified with PAS beads.
RESULTS
HSF2BP causes DNA damage sensitivity in somatic cells
We previously reported that transcripts encoding HSF2BP,
despite being restricted to the germline in mice, are detected
in all human cancer cell lines we tested, and that in some
tumor samples their levels approach those observed in nor-
mal testis (3). Analysis on the total protein extracts from
several cell lines by anti-HSF2BP immunoblotting (Supple-
mentary Figure S1A) was consistent with this varying de-
gree of expression and the presence of alternatively spliced
forms we described previously (3). This indicates that ei-
ther the HSF2BP promoter can be activated or the gene
can be amplified, in cancer cells of non-testicular origin.
To test the effect of ectopic activation of HSF2BP, we per-
formed RNAi and overproduction experiments in HeLa
and U2OS cells in which HSF2BP protein is hardly de-
tectable (Figure 1A and Supplementary Figure S1B), de-
spite the presence of the transcript (3).While knockdown of
HSF2BP did not affect clonogenic survival of U2OS cells,
increasing its ectopic production by stably expressing GFP-
taggedHSF2BP (GFP-HSF2BP) led to hypersensitization
to ICL-inducing agent MMC (Figure 1B). The effect was
reverted by RNAi against HSF2BP, confirming the speci-
ficity (Figure 1B). We further established that elevated pro-
duction of untagged human ormurineHSF2BP (hHSF2BP
and mHSF2BP, respectively) in Hela induced sensitivity to
MMC, cisplatin and the PARP inhibitor olaparib, while
not affecting cell viability (Supplementary Figure S1B–F).
Importantly, overproduction of HSF2BP did not sensitize
Hela or U2OS cells to ionizing radiation (Figure 1C, and
Supplementary Figure S1G), which indicates that HSF2BP
affects some, but not all, functions of BRCA2.
Genomic instability induced by HSF2BP could be bene-
ficial for tumor evolution, and mutations increasing its pro-
duction could be positively selected in tumors. To investi-
gate this, we searched for alterations inHSF2BP gene copy
number using the cBioPortal Cancer Genomics database
(53,54), and found that it is frequently amplified, reaching
1–2% in breast and ovarian cancers (Figure 1D). Moreover,
amplification ofHSF2BP rarely overlapped with mutations
in BRCA2, indicating that these events are likely mutually
exclusive (Figure 1E). This indicates that elevated levels of
HSF2BP, through its previously reported interaction with
BRCA2 (3), could play a role in cancer development.
HSF2BP inhibits the FA pathway
Hypersensitivity to DNA crosslinking agents and PARP
inhibitors in the absence of ionizing radiation sensitivity
or proliferation defects is more similar to the phenotype
of patient cells deficient in the FA proteins, rather than in
general HR components. Consistent with this, we found
no effect on DSB-induced direct repeat GFP gene conver-
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Figure 1. HSF2BP disrupts the FA pathway. (A–C) Immunoblot and clonogenic survivals of the U2OS cells stably transformed with GFP-hHSF2BP or
GFP expression constructs and stably transduced with lentiviral vectors encoding anti-HSF2BP (#2, #3) or non-targeting shRNAs. Cells were treated
with the indicated doses of MMC (B) or ionizing radiation (C); n = 2. Efficiency of the knockdown was assessed by immunoblotting of whole cell extracts
with the indicated antibodies (A); * indicates a non-specific band. (D) Frequency ofHSF2BP deletion and amplification in tumor sample sequencing data
available at cBioPortal (53,54). Studies with≥100 samples were analyzed. (E) Graphical summary of cancer samples that harbor genetic alteration in either
theHSF2BP or BRCA2 gene. Alteration frequency was calculated using profiled samples (562 alterations in 55 817 profiled samples forHSF2BP, and 2945
alterations in 68 793 profiled samples for BRCA2). Each sample was colored by alteration types as indicated. (F) Example metaphase chromosomal spread
from HSF2BP-overproducing cell treated overnight with 100 nMMMC. Chromatid breaks and a quadriradial chromosome are indicated with single and
double arrows, respectively. (G) Quantification of chromatid breaks in HeLa cells stably transformed with HSF2BP expression vectors or control, with and
without overnight 100 nM MMC treatment; 50 metaphases per condition were scored. (H) ICL repair efficiency in the presence or absence of HSF2BP.
The scheme on the left shows pICL, a synthetic plasmid substrate in which the diagnostic SapI site is disrupted by a cis-platinum ICL that is restored by
replication-associated repair by the FA pathway inXenopus egg extracts (see also (Supplementary Figure S3A) for details). pICL was replicated inXenopus
egg extract that was supplemented with purified recombinant His-tagged human (h) or Xenopus (x) HSF2BP or buffer. Replication intermediates were
isolated and digested with HincII, or HincII and SapI, and separated on agarose gel. Repair efficiency was calculated and plotted. As repair kinetics and
absolute efficiency are highly dependent on the egg extract preparation, single experiment is plotted here, and a replica is shown in (Supplementary Figure
S1L). #, SapI fragments from contaminating uncrosslinked plasmid present in varying amounts in different pICL preparations.
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sion in HSF2BP-overproducing cells (Supplementary Fig-
ure S1H), indicating that HR at restriction enzyme-induced
DSBs was functional. Furthermore, HSF2BP induced a
drastic increase in chromosomal aberrations, including ra-
dial chromosome formation, after treatment with MMC,
another hallmark of FA patient cells (Figure 1F and G).
These data suggest that ectopic production of HSF2BP
specifically affects the role of BRCA2 in ICL repair by the
FA pathway. Consistent with the specific effect, we found
that BRCA2 concentration was not changed (Supplemen-
tary Figure S1I), and nuclear localization of BRCA2 was
not affected (Supplementary Figure S1J) by HSF2BP over-
production.
To examine whether HSF2BP directly acts in the FA
pathway of ICL repair, we took advantage of the evolution-
ary conservation of the HSF2BP–BRCA2 interaction (3)
and made use of the Xenopus egg extract-based ICL repair
system. This system fully recapitulates the repair of a single,
site-specific cisplatin ICL situated on a plasmid, in a DNA
replication- and FA pathway-dependent manner (43,49,55).
We replicated the ICL-containing plasmid (pICL) in Xeno-
pus egg extract, which does not contain detectable endoge-
nous Xenopus laevisHSF2BP, in the presence or absence of
recombinant HSF2BP. Replication intermediates were iso-
lated and repair efficiency was determined bymeasuring the
regeneration of a SapI recognition site that is blocked by the
ICL prior to repair (Figure 1H). Addition of recombinant
human or Xenopus HSF2BP reduced ICL repair efficiency
by 70–80% (Figure 1H; Supplementary Figure S1K and L).
These data strongly suggest that the sensitivity of cells ec-
topically producing HSF2BP to ICL-inducing agents is due
to the inhibition of ICL repair by the FA pathway.
HSF2BP–BRCA2 interaction mediates FA pathway inhibi-
tion
Next, we examined whether direct interaction between
HSF2BP and BRCA2 is required for ICL repair inhibi-
tion by disrupting the interactions sites of both proteins.
In sharp contrast to wild-type HSF2BP, addition of the
R200T mutant, which does not interact with BRCA2 as
we previously showed (3), did not reduce ICL repair effi-
ciency in Xenopus egg extract (Figure 2A and Supplemen-
tary Figure S2A). Consistent with this, the production of
HSF2BP R200T did not sensitize U2OS cells to MMC
(Figure 2B). In previous work, we reported that most of
the HSF2BP-interacting region is encoded by exon 12 of
the BRCA2 gene (3). To disrupt this region, we took ad-
vantage of a naturally occurring minor splice form of the
BRCA2 transcript (56–59), in which exon 12 is skipped
but the reading frame is preserved. We predicted that this
BRCA2Δ12/Δ12 isoform would be resistant to the inhibitory
effect of HSF2BP and engineered variant HeLa cell lines, in
which we excised exon 12 from both alleles of the BRCA2
gene by CRISPR/Cas9 (Figure 2C and Supplementary Fig-
ure S2B). As we predicted, the BRCA2Δ12/Δ12 cells were
not sensitized to ICL-inducing agents and PARP inhibi-
tion upon ectopic HSF2BP expression, while BRCA2wt
cells were (Figure 2D–G). Importantly,BRCA2Δ12/Δ12 cells
were not hypersensitive to ICL-inducing agents in absence
of ectopic HSF2BP expression (Figure 2E and F). Thus,
HSF2BP inhibition of ICL repair requires direct interaction
with BRCA2.
HSF2BP inhibits homologous recombination in the FA path-
way
BRCA2 could act at various stages of ICL repair; it has
been assumed to play a role during HR, but it could also
act further upstream in the response to stalled replication
fork. To investigate which repair step is affected byHSF2BP
addition, we made use of the synchronous ICL repair reac-
tion in Xenopus egg extract (Supplementary Figure S3A).
Early key events in cisplatin ICL repair by the FA path-
way are FANCD2 monoubiquitination and the subsequent
nucleolytic incisions (10,60). Incubation of pICL in Xeno-
pus egg extract caused robust FANCD2 ubiquitination and
this was not affected by addition of hHSF2BP (Figure 3A).
Consistently, ectopic production of HSF2BP in human cells
also did not affect FANCD2 ubiquitination (Supplemen-
tary Figure S3B). We next investigated if ICL unhooking
was affected by HSF2BP. Unhooking incisions can be di-
rectly observed during ICL repair in egg extract by sep-
arating linearized replication intermediates on denaturing
agarose gels (Figure 3B and Supplementary Figure S3C).
The labeled parental strand migrates as a large X-shaped
structure and upon ICL unhooking it is converted to a lin-
ear molecule and arms (10,55). We replicated prelabeled
pICL in the presence and absence of hHSF2BP and mea-
sured the decline of the X-shape structures in time. How-
ever, no difference was observed in the presence or absence
of hHSF2BP indicating that ICL unhooking was not af-
fected by HSF2BP (Figure 3C).
After ICL unhooking, translesion synthesis (TLS) is ini-
tiated by the insertion of a nucleotide across from the un-
hooked adduct by a currently unknown polymerase, fol-
lowed by strand extension mediated by REV1 and poly-
merase  (Supplementary Figure S3A) (41,43). TLS can be
monitored by separating nascently labeled and linearized
pICL replication products on a denaturing agarose gel.
Stalled replication forks at the ICL initially generate arm
fragments and these are then converted to fully extended
linear fragments by TLS (Supplementary Figure S3A). Sub-
sequently, the incised strand will be repaired by HR result-
ing in the accumulation of additional full-length linear frag-
ments that are cleavable by SapI. Of note, the TLS prod-
ucts are not cleavable by SapI because the unhooked adduct
is not removed in Xenopus egg extract (43). We separated
HincII-digested nascent labeled repair products, whichwere
replicated in the presence and absence of hHSF2BP, on a de-
naturing agarose gel and quantified the accumulation of lin-
ear products (Figure 3D and Supplementary Figure S3D).
While linear products accumulated in both conditions, the
increase was less in the presence of HSF2BP (Figure 3E).
This could be caused by a defect in TLS and/or a defect in
HR. To address this, we examined the repair intermediates
after digestion with both HincII and SapI and found that
the accumulation of full-length linear products was very
similar in absence or presence of HSF2BP (Figure 3E). This
shows that TLS is not affected by the addition of HSF2BP,
and suggests that the reduction of linear products is caused
by a defect in HR. To address this directly, repair interme-
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Figure 2. FA pathway disruption by HSF2BP requires interaction with BRCA2. (A) ICL repair efficiency in Xenopus egg extract in the presence or
absence of purified recombinant wild-type (WT) human HSF2BP or its R200T variant that cannot bind BRCA2. #, SapI fragments from contaminating
uncrosslinked plasmid present in varying amounts in different pICL preparations. Repeat of this experiment is shown in (Supplementary Figure S2A). (B)
Clonogenic survival of U2OS cells stably producing GFP, or GFP-tagged wild-type or non-BRCA2-binding R200T variant of HSF2BP, and exposed to
the indicated doses of MMC; n= 4. (C) Schematic of a fragment of the human BRCA2 locus depicting the strategy for homozygous exon 12 excision from
HeLa cells using two CRISPR/Cas9 cuts. Introns are not drawn to scale; exon phase is depicted using various shapes of the side boundaries. Genotyping
primers are shown as blue arrows (see also (Supplementary Figure S2B)). Boundaries of the minimal HSF2BP-binding domain (HBD) mapped in the
previous study (fragment F9 (3)) is shown with green line. (D–G) Immunoblot (D) and clonogenic survival (E and F) of the BRCA2 Δ12 and its parental
HeLa cell line (wt), stably transformedwith humanHSF2BP expression vector (wild-type orR200Tmutant) or empty vector. (D)HSF2BP is indicated with
an arrow, * – non-specific band. For clonogenic survivals cells were treated with ICL-inducing agents MMC (E) and cisplatin (F), or PARPi talazoparib
(G); n = 3–9.
diates were linearized and analyzed by 2D gel electrophore-
sis (Figure 3F). In the absence of hHSF2BP, an X-arc was
formed indicating the presence of HR intermediates (11). In
contrast, the presence of wild-type hHSF2BP, but not the
R200T mutant, inhibited the formation of the X-arc (Fig-
ure 3G and Supplementary Figure S3E), providing further
evidence that HR during ICL repair is affected by HSF2BP.
HSF2BP reduces loading of RAD51 to ICLs
To address how HSF2BP inhibits HR during ICL repair,
we investigated BRCA2 and RAD51 recruitment to the
ICL-containing DNA. To this end, we pulled down the
crosslinked plasmid DNA during ICL repair in Xenopus
egg extract using streptavidin beads coated with biotiny-
lated LacI protein, which binds efficiently and nonspecifi-
cally to DNA (41) (Figure 4A). While this assay was not
sensitive enough to detect BRCA2, RAD51 was readily ac-
cumulated on pICL in the absence of hHSF2BP (Figure
4B). In contrast, no RAD51 was detected on pull downs
in the presence of hHSF2BP (Figure 4B). Consistent with
this, RAD51 accumulation at sites of MMC-induced dam-
age in human cells was significantly reduced by HSF2BP
(Figure 4C and D; Supplementary Figure S4A). To inves-
tigate the binding of BRCA2 specifically to the ICL site,
we then employed chromatin immunoprecipitations (ChIP;
Figure 4E). BRCA2 was immunoprecipitated from ICL re-
pair reactions in the presence and absence of HSF2BP,
and the co-precipitated DNAwas amplified by quantitative
PCR with primers specific to the ICL region. BRCA2 ac-
cumulated at the ICL during repair as previously described
(61). However, in the presence of HSF2BP, the accumula-
tion of BRCA2 at the site of damage was not only reduced,
but also more transient as BRCA2 levels returned to back-
ground faster compared to conditions inwhich noHSF2BP,
or HSF2BP R200T were added (Figure 4F). HSF2BP it-
self was recruited to the ICL in a BRCA2-dependent man-
ner as its wild-type form co-immunoprecipitated with the
pICL, while the R200T mutant did not (Figure 4G), which
is consistent with the defective HSF2BP DNA-damaged
induced focus formation observed for this mutant (3). In
contrast, recruitment of the unhooking endonuclease XPF,
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Figure 3. HSF2BP inhibits HR in the FA pathway. (A) HSF2BP does not inhibit ICL-induced FANCD2 ubiquitination in Xenopus egg extract. Proteins
from egg extract incubated with pICL with or without the addition of recombinant human HSF2BP for the indicated periods of time were analyzed by
immunoblotting with anti-Xenopus laevis FANCD2 antibody. (B and C) HSF2BP does not inhibit lesion unhooking in Xenopus egg extract. Prelabeled
pICL was replicated in Xenopus egg extracts supplemented with or without recombinant human HSF2BP, and replication products were isolated, digested
by HincII to generate the products shown on the scheme (B), and separated on a denaturing agarose gel (Supplementary Figure S3C). The decline of
the X-structures was quantified and plotted (C). Red lines on the scheme (B) indicate the labeled parental strand. (D and E) HSF2BP does not inhibit
translesion synthesis in Xenopus egg extract. pICL was replicated in Xenopus egg extracts supplemented with or without recombinant human HSF2BP in
the presence of 32P--dCTP, and replication products were isolated, digested by HincII, or HincII and SapI, as shown on the scheme (D), and separated
on a denaturing agarose gel (Supplementary Figure S3D). Extension products were quantified and plotted (E). HSF2BP-induced reduction in full-length
products in the absence of SapI indicates a defect in HR. (F and G) Inhibition of HR intermediate formation by HSF2BP revealed by 2DGE. pICL was
replicated in Xenopus egg extracts supplemented with or without recombinant human HSF2BP in the presence of 32P--dCTP, and replication products
were isolated, digested by HincII, and analyzed by 2DGE. Scheme (F) shows migration patterns for various replication products. The X-arc is indicated
by the blue arrows in the top right image in (G), the numbers indicate the efficiency of its formation (defined by the ratio of X-arc product intensity to total
intensity).
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Figure 4. HSF2BP–BRCA2 interaction prevents RAD51 accumulation at ICL. (A andB) Stable RAD51 accumulation on pICL during repair is abrogated
by wild-type human HSF2BP, but not the R200T mutant. The pICL plasmid was replicated in Xenopus egg extracts. At the indicated times, pICL was
pulled down by incubation with streptavidin beads coated with biotinylated LacI (A). Presence of bound RAD51 and FANCD2 was determined by
immunoblotting (B). (C andD) RAD51 focus formation after short-term (0–4 h) exposure to 1.2 MMMC of HeLa cells stably transformed with human
HSF2BP expression vector or an empty vector. Thirty minutes before fixation, EdU was added to the media to label S-phase cells. After Click-IT reaction
and anti-RAD51 immunofluorescent staining, cells were imaged using confocal microscope. Representative images (C) and foci quantification (D) are
shown. Foci were counted manually. The experiment was repeated two times, 50–90 nuclei per sample were analyzed, significance was determined using
one-way ANOVA; scale bars = 5 m. Experiment with chronic MMC treatment is shown in Supplementary Figure S4A. (E) Scheme of the ChIP assay. (F
andG) Recombinant humanHSF2BP inhibits loading of endogenous BRCA2 at the ICL inXenopus egg extract. pICL replication samples at the indicated
time points were analyzed by BRCA2 (F) and HSF2BP (G) ChIP using a primer pair for the ICL locus.
TLS polymerase REV1 and FANCD2 to the ICL was not
affected in the presence of HSF2BP (Supplementary Figure
S4B–D), further establishing that HSF2BP inhibits ICL re-
pair downstream of the FA pathway activation, ICL inci-
sion and TLS.
HSF2BP induces ICL repair-dependent unloading and degra-
dation of BRCA2
To gain mechanistic understanding of how BRCA2–
HSF2BP interaction prevents RAD51 loading, we mon-
itored the levels of BRCA2 during ICL repair in Xeno-
pus egg extract. Strikingly, in the presence of wild-type
HSF2BP, but not the R200T mutant, BRCA2 was pro-
gressively degraded during repair (Figure 5A). Addition of
the proteasome inhibitor MG-132, in combination with re-
combinant ubiquitin to prevent ubiquitin depletion, fully
blocked BRCA2 degradation during ICL repair indicating
that the degradation is proteasome-mediated (Figure 5B).
The degradation was ICL-dependent, as it was not induced
when a non-damaged control plasmid was replicated in the
presence of hHSF2BP (Figure 5C). In addition, the degra-
dation is initiated upstream of nucleolytic incisions that un-
hook the ICL, because blocking these incisions by immun-
odepletion of XPF-ERCC1 still resulted in BRCA2 degra-
dation (Supplementary Figure S5A). To examine whether
the reduced levels of BRCA2 at the ICL in the presence of
hHSF2BP (Figure 4F) are directly caused byBRCA2 degra-
dation, we performed ChIP on repair intermediates gener-
ated in the presence of MG-132. Surprisingly, even though
BRCA2 is not degraded under these conditions, its presence
at the ICL is still reduced to the same extent compared to the
condition without proteasomal inhibition (Figure 5D and
Supplementary Figure S5B). Consistent with this, protea-
somal inhibition did not rescue the HSF2BP-induced ICL
repair defect (Figure 5E and Supplementary Figure S5C).
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Figure 5. HSF2BP induces ICL-dependent BRCA2 degradation. (A) Wild-type HSF2BP, but not the R200T mutant, induces BRCA2 degradation during
ICL repair. pICL was replicated inXenopus egg extracts in the presence or absence of humanHSF2BP. Total extract samples were collected at the indicated
time points and analyzed by immunoblotting. (B) HSF2BP-induced BRCA2 degradation is proteasome dependent. pICL was replicated in Xenopus egg
extracts containing human HSF2BP in the absence or presence of proteasome inhibitor MG-132. Recombinant His-FLAG-tagged ubiquitin was added
to counteract ubiquitin depletion as a result of proteasome inhibition. Total extract samples were collected at the indicated time points and analyzed by
immunoblotting. (C) HSF2BP-induced BRCA2 degradation is ICL repair-dependent. Experiment as in (A) was repeated with the pControl plasmid that
has the same sequence as pICL, but no crosslink. Total extract samples were collected at the indicated time points and analyzed by immunoblotting. (D)
Addition ofMG-132 does rescue reduced level of BRCA2 at ICLs during repair. Crosslinked plasmids were replicated in the presence or absence of purified
recombinant wild-type human HSF2BP, with and without MG-132 and His-FLAG-tagged ubiquitin. Samples were analyzed by BRCA2 ChIP using a
primer pair for the ICL locus. (E) HSF2BP-induced ICL repair defect is not rescued upon addition ofMG-132. ICL repair efficiency inXenopus egg extract
was measured in the presence or absence of purified recombinant wild-type human HSF2BP with and without MG-132 and His-FLAG-tagged ubiquitin.
#, SapI fragments from contaminating uncrosslinked plasmid present in varying amounts in different pICL preparations. (F) Schematic depiction of the
model explaining HSF2BP effects on the function of BRCA2 in DSB and ICL repair.
These findings indicate that the repair defect is caused by
the HSF2BP-mediated removal of BRCA2 from the ICL
and that BRCA2 degradation by the proteasome is a down-
stream event. Ubiquitin-mediated extraction of proteins
from the chromatin is often mediated by the p97 segregase
(62) and allows subsequent proteasomal degradation. Con-
sistent with a similar model, we detected potential ubiquitin
chains on BRCA2 upon proteasome inhibition (Figure 5B),
and addition of a p97 inhibitor preventedHSF2BP-induced
BRCA2 degradation (Supplementary Figure S5D). Taken
together, we propose that HSF2BP promotes BRCA2 ubiq-
uitination at ICL sites that leads to its p97-dependent ex-
traction from the chromatin, preventing stable RAD51 ac-
cumulation at the ICL, leading to inhibition of HR.
DISCUSSION
Our findings detail the molecular mechanism by which ec-
topic production of a meiotic HR protein HSF2BP neg-
atively affects ICL repair in somatic tumor-derived cells.
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They provide experimental evidence in support of the ap-
pealing but not extensively tested hypothesis that meiotic
DNA metabolism, when induced out of context, could
induce transformation-promoting genomic instability. Ec-
topic expression of germline genes has been previously
shown to either increase (23,28–29,63–66) or decrease (21–
22,25,27,30) the resistance of cancer cells to DNA dam-
age. While both effects can promote tumor development,
genome destabilization is expected to be more relevant in
the initial stages of carcinogenic transformation. Impor-
tantly, we find that HSF2BP amplification is mutually ex-
clusive with pathological BRCA2 mutations, suggesting it
could drive tumorigenesis by inducing genome instability.
While HSF2BP promotes HR during meiosis (3,4), we
describe how it suppresses HR during ICL repair in somatic
cancer cells. This apparent contradiction is not surprising
taking into account the major differences between mitotic
and meiotic DNA transactions. For example, while in mi-
totic cells BRCA2 functions to chaperone only the RAD51
strand exchange protein, during meiosis it needs to orches-
trate homologous recombination activities between both
RAD51 and DMC1. Given the proximity of the HSF2BP
binding domain (2270–2337) to the two DMC1-binding
sites in BRCA2: the region containing the PhePP motif
(2386–2411) (67) and the BRC repeats 6–8 (68) (1837–
2085), it is possible that the HSF2BP–BRCA2 interaction
is required for the formation of the combined RAD51-
DMC1 nucleoprotein filament at meiotic DSBs, but cre-
ates a degradation-inducing BRCA2 conformation when
DMC1 is absent during the ICL repair in mitosis. How-
ever, as the substitution of phenylalanine 2406, a residue re-
ported to be essential for DMC1 binding in vitro (67), with
aspartic acid had no effect on fertility in mice (69), and the
role of BRC6–8 in meiosis has not been tested in vivo, the
relevance of the proximity is unclear.
The effect of HSF2BP on BRCA2 in cancer cells is highly
specific as it manifests only in the context of PARPi resis-
tance and ICL repair by the FApathway, effectively creating
a separation of function condition for BRCA2. This obser-
vation has several important implications. First, we believe
this is more consistent with the putative role in transfor-
mation, as it emerges that gradual or segmental losses of
BRCA2 function are more conducive to tumorigenesis (70–
72) compared to the catastrophic consequences of its com-
plete inactivation, which generally leads to cell death. The
interplay between HSF2BP activity and the production of
BRCA212 splice form could provide additional plasticity
in modulating BRCA2 function. Second, it creates a vulner-
ability that can be targeted by specific therapies, as exempli-
fied by the acute sensitivity of HSF2BP-producing cells to
PARPi. Third, the ability to experimentally isolate BRCA2
function in ICL repair from its other roles provides a tool
for further mechanistic understanding of this complex es-
sential protein. This could be of similar importance as the
previous identification of mutations that specifically affect
BRCA2′s role in replication fork stabilization (73,74).
The similarity of the cellular phenotype induced by
HSF2BP to that of FA patient cells raises an interesting
possibility that FA-like genomic instability syndromes may
not require any mutations affecting protein sequences. Al-
though this is a well-established concept in molecular on-
cology (proto-oncogene activation) and there are examples
of genetic diseases and developmental abnormalities caused
by ectopic gene expression in humans and in model organ-
isms (75–78), ectopic activation of wild-type genes is out-
side of the current FA diagnostic paradigm. The same ap-
plies to genetic analysis of HR-deficient tumors, which gen-
erally does not take HR attenuators into account as a pos-
sible cause. Therefore, the identification and monitoring of
these ectopically expressed genes could facilitate diagnosis
and allow better treatment options.
Our findings also open up a newway to study the origin of
PARPi sensitivity in FA cells, which currently not well un-
derstood. Interestingly, sensitization to PARPi by ectopic
HSF2BP production is closer to the levels observed in cells
deficient in FA core (79–82) compared to cells deficient in
HR proteins (BRCA2, PALB2, RAD51, BRCA1), which
are much more sensitive. This indicates that BRCA2 con-
tributes to PARPi resistance via multiple pathways, some
of which also may also involve the FA core proteins. The
phenotype of HSF2BP-producing cells also suggests that
response to ionizing radiation is not a universal predictor
of cancer cell ‘BRCAness’, as they are not sensitive to the
irradiation, but are sensitive to PARPi and ICL-inducing
agents.
Biochemical recapitulation of ICL repair in Xenopus egg
extracts revealed no effect on the initial steps of repair (FA
pathway activation, ICL unhooking and TLS), but defec-
tive HR due to ICL repair-dependent removal of BRCA2
from the lesion followed by BRCA2 degradation prevent-
ing stable RAD51 loading. This, together with our previ-
ous finding that BRCA2 and HSF2BP are in a constitu-
tive complex, leads us to the following model (Figure 5F).
During ICL repair, the HSF2BP–BRCA2 complex is effi-
ciently recruited to the ICL, where the presence of HSF2BP
causes local BRCA2 ubiquitination and removal of the pro-
tein from the lesion site by the p97 segregase. Once re-
moved from the chromatin, BRCA2 is efficiently degraded
by the proteasome. In the absence of the mediator func-
tion of BRCA2, RAD51 nucleoprotein filaments cannot
be stably formed at the lesion, leading to the failure of
downstream HR steps that depend on homology search
and strand exchange. Although it is currently not clear
what triggers HSF2BP-mediated BRCA2 ubiquitination,
we show that its degradation does not depend on the gener-
ation of the DSB by XPF-ERCC1-dependent unhooking.
This indicates that ubiquitination and BRCA2 unloading
are initiated upstream during ICL repair. Since BRCA2 is
known to be recruited to and stabilize stalled replication
forks (73,74), we speculate that the recruitment and degra-
dation could be coupled, possibly by an HSF2BP-mediated
interaction with a stalled fork-associated ubiquitin E3 lig-
ase. Although this model is speculative, it would explain
whyHSF2BP does not compromise those forms of BRCA2-
dependent HR that are not preceded by a stalled replica-
tion fork, and why HSF2BP-producing cells are sensitive to
PARPi.
Further investigation of the meiotic defect caused by
HSF2BP loss and ICL repair suppression by its ectopic pro-
duction should provide exciting details about BRCA2 roles
in HR, allow to better reconcile the seemingly disparate
functions of HSF2BP, establish themolecular details of FA-
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HR engagement and advance the understanding of the ge-
netic underpinnings of FA and cancer.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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